Zogenix to Release Third Quarter 2020 Financial Results and Host Conference Call and Webcast on November 10
Zogenix, a biopharmaceutical company focused on rare disease therapies, will report its financial results for the third quarter of 2020 on November 10, 2020, at 4:30 PM ET.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Zogenix, a biopharmaceutical company focused on rare disease therapies, will report its financial results for the third quarter of 2020 on November 10, 2020, at 4:30 PM ET. The company’s lead product, FINTEPLA, is approved for treating seizures in Dravet syndrome and is under development for other conditions. Zogenix is committed to transforming patient lives with innovative therapies. The conference call will offer insights into the company’s financial performance and ongoing projects.
Positive
- Zogenix's FINTEPLA has received FDA approval for Dravet syndrome, indicating strong regulatory progress.
- The company is advancing late-stage development for additional rare disease therapies, enhancing growth potential.
Negative
- None.
Details
News Market Reaction – ZGNX
The recorded move for ZGNX in the trading session of this news was -2.63%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
EMERYVILLE, Calif., Oct. 26, 2020 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ: ZGNX), a global biopharmaceutical company developing rare disease therapies, today announced that it will report its financial results for the three and nine months ended September 30, 2020 and host a corporate update conference call and webcast after the market close on Tuesday, November 10, 2020, at 4:30 PM Eastern Time.
| Conference Call Details | |
| Tuesday, November 10, at 4:30 PM Eastern Time / 1:30 PM Pacific Time | |
| Toll Free: | 877-407-9716 |
| International: | 201-493-6779 |
| Conference ID: | 13711927 |
| Webcast: | http://public.viavid.com/index.php?id=141969 |
About Zogenix
Zogenix is a global biopharmaceutical company committed to developing and commercializing therapies with the potential to transform the lives of patients and their families living with rare diseases. The company’s first rare disease therapy, FINTEPLA® (fenfluramine) oral solution has been approved by the U.S. FDA and received a positive CHMP opinion in Europe for the treatment of seizures associated with Dravet syndrome, a rare, severe childhood onset epilepsy. The company has two additional late-stage development programs underway: one for FINTEPLA for the treatment of seizures associated with Lennox-Gastaut syndrome, a different rare childhood-onset epilepsy and another for MT1621, an investigational novel substrate enhancement therapy for the treatment of TK2 deficiency, a rare genetic disorder. MT1621 is being developed through Modis Therapeutics, a Zogenix company.
Zogenix
Melinda Baker
Senior Director, Corporate Communications
+1 (510) 788-8732 | corpcomms@zogenix.com
Investors
Brian Ritchie
Managing Director, LifeSci Advisors LLC
+1 (212) 915-2578 | britchie@lifesciadvisors.com
Media
In Europe: Kerry Lloyd-Jones, Account Director, Porter Novelli
+44 (0) 7949 794 290 | kerry.lloyd-jones@porternovelli.co.uk
In the US: Stefanie Tuck, Vice President, Porter Novelli
+1 (978) 390-1394 | stefanie.tuck@porternovelli.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.